Polygenic risk scores (PRS) are being explored as tools to stratify inherited disease risk, but clinical translation requires demonstration that a score derived in one population retains discriminatory power in independent cohorts. For suspected familial hypercholesterolemia (FH), many patients who meet clinical criteria lack a detectable monogenic cause and are presumed to carry a polygenic LDL-C burden. This study tested whether a published hypercholesterolemia PRS (PGS000936) maintains discriminatory value and can stratify risk in an independent German clinical and population sample.
The authors applied PGS000936, a published score spanning 5,386 genome-wide loci, to genotyped data from 117 monogenic-negative hypercholesterolemia cases and 496 controls drawn from the German general population. Samples were genotyped on the Illumina Global Screening Array v3.0 and imputed to approximately 11 million variants. The PRS was applied without retraining: externally derived β-coefficients were used to compute scores in the German dataset. The study reports application details but does not provide full demographic breakdowns or detailed imputation quality metrics in the source text.
The PRS distinguished cases from controls with very strong statistical significance (p < 2×10-16). Mean PRS values differed substantially between groups: cases had a mean PRS of 0.97, while controls had a mean PRS of 0.52. These group-level differences indicate that PGS000936 captures a component of genetic liability to hypercholesterolemia even when applied to an external cohort without model retraining.
To quantify stratification, the authors performed decile analysis of the PRS distribution. Individuals in the top 10% of the PRS distribution showed markedly increased odds of being a hypercholesterolemia case: odds ratio (OR) 7.55 with 95% confidence interval 4.36–13.07 (p < 0.0001). This seven-fold increase in odds for the highest decile demonstrates the score’s potential to identify a subgroup with elevated genetic risk compared with the remainder of the population.
Clinical lipid data were available for a subset of 94 cases. In this subset, higher PRS values were associated with significantly higher LDL-C levels measured before treatment initiation. The source reports this association but does not provide the numeric effect size or model covariates in the abstract; those details were not reported in the source text provided here.
A notable observation was that the PRS distribution in the German control cohort was shifted relative to the control cohort in the initial study that derived PGS000936. The authors highlight that this shift implies population-specific differences in PRS distributions and underscores the need for population-matched calibration when estimating odds ratios or interpreting individual PRS values. Without local calibration, absolute PRS values and derived risk estimates may be misleading.
The study was approved by the Ethics Committee at Leipzig University (approval no. 222 402-16ek). All participants provided written informed consent for genetic analyses and use of pseudonymized data for research. The authors declare no competing interests. Data sources referenced include the UK Biobank and the PGS Catalog entry for PGS000936; the source lists https://www.ukbiobank.ac.uk/ and https://www.pgscatalog.org/score/PGS000936/ as repositories. The manuscript is posted on medRxiv as a preprint and has not been peer reviewed; it should not be used to guide clinical practice.
This external validation shows that the published hypercholesterolemia PRS PGS000936 retains discriminatory power and can stratify genetic risk in a real-world German setting when applied without retraining. Key implications are that the score can identify individuals with elevated genetic burden (notably those in the top decile) and that PRS values associate with pre-treatment LDL-C levels in affected individuals.
However, the presented source does not report some details necessary to fully evaluate clinical implementation: full demographic characteristics of cases and controls, detailed imputation quality metrics, numerical effect sizes for the LDL-C association, reclassification statistics (e.g., net reclassification improvement), and prospective outcome data. The authors also stress the requirement for population-matched calibration because PRS distributions differ between cohorts; this is critical for accurate odds estimation and interpretation at the individual level.
Overall, the findings support the clinical utility of PGS000936 for risk stratification in hypercholesterolemia when locally calibrated, while noting that the manuscript is a preprint pending peer review and that additional data would be required before routine clinical use.